[Systemic therapy for colorectal cancer].

By B. Pestalozzi, D. Jäger, A. Knuth. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2005

627 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. (2009, background): “Treatment options for mCRC nowadays include the chimeric IgG1 monoclonal antibody (moAb) cetuximab and the fully humanized IgG2 moAb panitumumab (2, 3).”
Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 Patients (2009, background): “While chemotherapy alone is rarely, if ever, associated with durable survival, modern chemotherapy now results in median survival of up to 21 months in patients with unresectable disease.(31) The combination of modern chemotherapy with advances in surgical techniques has resulted in improvements in ”